|Day Low/High||3.35 / 3.35|
|52 Wk Low/High||0.44 / 45.82|
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Northern District of California on behalf...
Doug Kass shares his views on Potash, Radian and oil, and revisits his prediction about KaloBios.
As Wall Street prepares to close out 2015 much where it started, investors looked to the year ahead to determine direction on the second-last day of trading.
Stocks move slightly lower as another selloff in crude oil prices hits the energy sector.
KaloBios Pharmaceuticals (KBIO), the drugmaker that fired CEO Martin Shkreli less than two weeks ago, filed for Chapter 11 bankruptcy on Tuesday.
Stocks pull back on Wednesday morning as crude oil returns to a level below $37 a barrel.
U.S. stock futures are dipping somewhat Wednesday as oil prices weaken, despite a strong showing in the markets on Tuesday.
The weak outlook for oil prevails, and oil prices are sliding back toward an 11-year low.
U.S. stock futures are pointing lower in what's expected to be a quiet trading session ahead of the Christmas holiday.
Rosen Law Firm, a global investor rights law firm, announces that a class action lawsuit has been filed on behalf of purchasers of KaloBios Pharmaceuticals, Inc.
Levi & Korsinsky, LLP announces that it has commenced an investigation of KaloBios Pharmaceuticals, Inc.
Khang & Khang LLP announces that it is investigating claims of potential misrepresentations by KaloBios Pharmaceuticals, Inc.
Doug Kass shares another reason he's shorting Apple and why KaloBios could hit $0.
Martin Shkreli resigned as chief executive officer of Turing Pharmaceuticals Friday following his arrest on charges of securities fraud.